Adaptive robust control of cancer chemotherapy in the presence of parametric uncertainties: A comparison between three hypotheses

In this paper, an adaptive robust control strategy is developed for the manipulation of drug usage and consequently the tumor volume in cancer chemotherapy. Three nonlinear mathematical cell-kill models including log-kill hypothesis, Norton-Simon hypothesis and E(max) hypothesis are considered in the presence of uncertainties. The Lyapunov stability theorem is used to investigate the global stability and tracking convergence of the process response. For the first time, performance of the uncertain process is investigated and compared for three nonlinear models. In addition, the effects of treatment period, initial value of tumor volume (carrying capacity) and the uncertainty amount on dynamic system behaviour are studied. Through a comprehensive evaluation, results are presented and compared for three cell-kill models. According to the results, for a wide range of model uncertainties, the adaptive controller guarantees the robust performance. However, for a given treatment period, more variation in drug usage is required as the amount of model uncertainty increases. Moreover, for both the nominal and uncertain models, less drug usage is required as the treatment period increases.

[1]  John Carl Panetta,et al.  Optimal Control Applied to Competing Chemotherapeutic Cell-Kill Strategies , 2003, SIAM J. Appl. Math..

[2]  Ami Radunskaya,et al.  A mathematical tumor model with immune resistance and drug therapy: an optimal control approach , 2001 .

[3]  J. M. Murray,et al.  Some optimal control problems in cancer chemotherapy with a toxicity limit. , 1990, Mathematical biosciences.

[4]  Andrzej Swierniak,et al.  Singularity of optimal control in some problems related to optimal chemotherapy , 1994 .

[5]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.

[6]  Gholamreza Vossoughi,et al.  Optimal robust control of drug delivery in cancer chemotherapy: A comparison between three control approaches , 2013, Comput. Methods Programs Biomed..

[7]  J. M. Murray,et al.  Optimal control for a stochastic model of cancer chemotherapy. , 2000, Mathematical biosciences.

[8]  Weiping Li,et al.  Applied Nonlinear Control , 1991 .

[9]  John A. Adam,et al.  A mathematical model of cycle-specific chemotherapy , 1995 .

[10]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[11]  Z. Agur,et al.  A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. , 1992, Mathematical biosciences.

[12]  S. Sager,et al.  Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function. , 2011, Mathematical biosciences.

[13]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[14]  John Carl Panetta,et al.  Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy , 2000, SIAM J. Appl. Math..

[15]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[16]  Pei Wang,et al.  Sensor-based cell and tissue screening for personalized cancer chemotherapy , 2011, Medical & Biological Engineering & Computing.

[17]  J. M. Murray,et al.  Optimal control for a cancer chemotherapy problem with general growth and loss functions. , 1990, Mathematical biosciences.

[18]  R. B. Martin,et al.  Optimal control drug scheduling of cancer chemotherapy , 1992, Autom..

[19]  Urszula Ledzewicz,et al.  Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments , 2009, Proceedings of the 48h IEEE Conference on Decision and Control (CDC) held jointly with 2009 28th Chinese Control Conference.

[20]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[21]  L B Sheiner,et al.  Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.

[22]  A. Murugan,et al.  Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.

[23]  Carlos Eduardo Pedreira,et al.  Optimal schedule for cancer chemotherapy , 1991, Math. Program..

[24]  M. Alamgir Hossain,et al.  Multi-objective optimal chemotherapy control model for cancer treatment , 2010, Medical & Biological Engineering & Computing.

[25]  J. L. Boldrini,et al.  The influence of fixed and free final time of treatment on optimal chemotherapeutic protocols , 1998 .

[26]  G. W. Swan Role of optimal control theory in cancer chemotherapy. , 1990, Mathematical biosciences.

[27]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[28]  G. W. Swan,et al.  General applications of optimal control theory in cancer chemotherapy. , 1988, IMA journal of mathematics applied in medicine and biology.

[29]  Alberto Gandolfi,et al.  The Norton–Simon hypothesis and the onset of non-genetic resistance to chemotherapy induced by stochastic fluctuations , 2012 .

[30]  Brent D. Weinberg,et al.  Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants , 2008, Medical & Biological Engineering & Computing.

[31]  Lewis B Sheiner,et al.  Determination of maximum effect. , 2002, Clinical pharmacology and therapeutics.